|
||||||||||||||||||||
|
CMS Crosswalk Update Romidepsin, J9318: Published Medicare Payment Limit |
||||||||||||||||||||
|
Effective October 1, 2026, Amneal Pharmaceuticals romidepsin solution, NDC 70121-2250-01, appears in the CMS ASP NDC-HCPCS crosswalk under HCPCS J9318, with a Medicare Part B payment limit established in the Q4 2026 (October 2026) ASP pricing file. Payers and providers should update their systems and records accordingly to ensure accurate billing and reimbursement. Full pricing detail is below. |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
*The above 11-digit NDC code is used for claims processing and reimbursement. |
||||||||||||||||||||
|
Important Safety Information & Indication |
||||||||||||||||||||
|
Romidepsin injection solution is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least one prior systemic therapy. The most common adverse reactions associated with romidepsin injection solution include nausea, fatigue, infections, vomiting, anorexia, electrocardiogram ST-T wave changes, dysgeusia, constipation and pruritus. Grade 3-4 laboratory abnormalities (≥ 10%) include lymphopenia, neutropenia, anemia and thrombocytopenia. Please see full Prescribing Information by clicking here. |
||||||||||||||||||||
|